Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 520 across all filing types
Latest filing 2025-02-25 Legal Proceedings Report
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a specific corporate/regulatory event: the FDA's acceptance of a Supplemental New Drug Application (sNDA) for UZEDY® for a new indication (Bipolar I Disorder). This type of announcement, detailing clinical/regulatory milestones and partnership updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on a specific, time-sensitive operational/regulatory update rather than comprehensive financial results (like a 10-K or IR) or a general regulatory filing fallback, 'ER' (Earnings Release) is the closest fit among the options for a major operational announcement, although 'RNS' (Regulatory Filings) is also plausible. Given the structure and content (key highlights, partnership details, regulatory progress), it functions as an immediate public disclosure of a significant event, aligning best with the function of an Earnings Release or a major operational update announcement. Since it is a full press release detailing a regulatory event, and not just a short notice about a report being available, I will classify it as an Earnings Release (ER) as these often contain operational/regulatory news alongside financial context, or RNS if ER is too focused on quarterly results. Since it is a press release announcing a regulatory milestone, and not a quarterly financial report, RNS is the most appropriate general regulatory announcement category if ER is reserved strictly for quarterly financial summaries. However, in many databases, major operational announcements like this are grouped with ERs. Given the options, and the fact that it is a formal announcement of a significant development, I will lean towards RNS as the most accurate catch-all for non-standard, time-sensitive regulatory/operational news that isn't a full financial report or a specific management change.
2025-02-25 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document text is a press release announcing that the FDA has accepted the Supplemental New Drug Application (sNDA) for UZEDY for the treatment of Bipolar I Disorder. It details the drug's indication, safety warnings (including boxed warnings like 'INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS'), contraindications, and adverse reactions. This content structure—a formal announcement regarding regulatory action on a drug application, including detailed safety information—is characteristic of a regulatory filing announcement or a press release accompanying such an event. Since it is an announcement about a regulatory submission (sNDA acceptance) and not the final comprehensive report (like a 10-K or IR), and it is not a general regulatory filing (RNS) or a report publication announcement (RPA), the most fitting category among the provided options that covers specific regulatory/legal updates, especially concerning drug applications and safety profiles, is not explicitly listed. However, the core subject is a regulatory action concerning a drug. Given the options, this is a highly specific announcement. It is not an Earnings Release (ER), Interim Report (IR), or a general management discussion (MDA). It is a specific announcement related to drug development and regulatory status. Since there is no 'Regulatory Submission Update' or 'Drug Filing Announcement' category, I must choose the closest fit. It is not a Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV). It is a formal announcement of a regulatory event. If we consider 'LTR' (Legal Proceedings Report) as a broad category for regulatory/legal matters, it might fit, but this is a positive regulatory step, not a proceeding. Given the context of pharmaceutical filings, this is a specific corporate announcement. Since it is a detailed announcement about a regulatory submission and its implications, and it doesn't fit the definitions of ER, IR, 10-K, or CT, the best fit among the provided specific codes is difficult. However, if we interpret the document as a formal announcement of a significant corporate event related to product approval/filing, and lacking a better fit, 'RPA' (Report Publication Announcement) is sometimes used for major announcements, but this is more specific. Given the nature of the content (FDA acceptance of an sNDA), it is a highly specific corporate/regulatory update. Since it is a detailed press release announcing a regulatory milestone, and not the final comprehensive report, 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings - fallback) are possibilities. Because it is a detailed press release announcing a specific regulatory milestone (FDA acceptance), and not just announcing that *another* report is attached, I will lean towards the most general regulatory/corporate announcement category that isn't a specific report type. 'RNS' is the fallback for miscellaneous filings. I will classify this as a specific corporate announcement that doesn't fit the other detailed categories, leaning towards RNS as a broad regulatory announcement, or RPA if interpreted as announcing the 'publication' of this news. Given the length and detail, it is a primary announcement. I will select RNS as the most appropriate general regulatory announcement fallback, as it is not a standard financial report (10-K, IR) or a specific corporate action like M&A or Dividend. Upon re-evaluation, this is a press release announcing a regulatory milestone, which often falls under general regulatory news. RNS is the best fit for a non-standard, specific regulatory/corporate news item not covered elsewhere.
2025-02-25 English
Inside Information / Other news releases
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a successful capital raise (Global Offering) of €42.9 million through the issuance of new shares. It details the pricing, the investors involved, the use of proceeds, and the impact on share capital. This falls under the category of share issuance and capital changes, as it describes the creation and sale of new equity to investors.
2025-02-19 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 100% confidence The document is a press release from Medincell announcing the successful completion of a global capital raise (Offre Globale) totaling 42.9 million euros through a private placement and a public offering via PrimaryBid. It details the number of new shares issued, the subscription price, the impact on shareholding structure, and the intended use of proceeds. This falls squarely under the definition of a capital/financing update.
2025-02-19 French
Inside Information / Other news releases
Capital/Financing Update Classification · 100% confidence The document is a press release issued by Medincell announcing a 'Global Offering' of approximately 10% of its share capital through a private placement and a public offering via PrimaryBid. It details the purpose of the capital raise, the offering structure, lock-up commitments, and financial intermediaries involved. This falls under the category of capital/financing updates as it describes a specific corporate action to raise funds through the issuance of new shares.
2025-02-18 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Medincell announcing a 'Global Offering' (Offre Globale) of shares representing approximately 10% of its capital stock. It details the structure of the capital increase, including a private placement for institutional investors and a public offering via the PrimaryBid platform. This falls under the category of share issuance and capital changes, as it describes the mechanics of a new share issue and the associated capital structure adjustment.
2025-02-18 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.